340B Orphan Drug Exclusion: How Entity Type and Designation Apply

Start with the entity type, not the diagnosis

In hospital pharmacy purchasing, revenue-cycle management, and specialty market-access operations, teams frequently evaluate 340B Drug Pricing Program eligibility by inspecting the patient chart: the diagnosis code, the clinical indication, or the specific FDA-approved label under which a medication was administered. For the orphan-drug exclusion established by Section 340B(e) of the Public Health Service Act (42 U.S.C. § 256b(e)), that sequence is fundamentally inverted. Starting with the clinical indication is not merely inefficient—it is an operational trap that contradicts federal statute and binding case law.

The 340B orphan-drug exclusion operates as a strict, two-gate statutory test. The first gate evaluates the covered entity's legal enrollment category in the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs Information System (OPAIS). The second gate evaluates the product's regulatory designation status in the Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) database. Neither gate examines patient medical records, billing claim diagnoses, commercial payer formulary coverage, or whether the prescribed use is for an ultra-rare condition or a highly prevalent common disease.

To determine whether a manufacturer owes a statutory 340B ceiling-price offer on a given drug at a given facility, operations teams must execute a four-step sequential workflow:

1. Verify OPAIS Enrollment Type: Look up the hospital's registered 340B Covered Entity ID in the federal OPAIS database. Determine the precise facility classification and map it to the corresponding subparagraph of 42 U.S.C. § 256b(a)(4).

2. Check § 256b(e) Ineligibility: Determine whether the statutory subparagraph is enumerated in 42 U.S.C. § 256b(e). If the facility is enrolled as a Disproportionate Share Hospital (DSH), Children's Hospital, or federal grantee clinic, the orphan exclusion does not apply. The analysis then returns to whether the product is otherwise a covered outpatient drug under SSA § 1927(k).

3. Query FDA OOPD Designation Status: If the facility is one of the four hospital types subject to § 256b(e), query the public FDA OOPD database under 21 U.S.C. § 360bb. If the drug has an active status of Designated or Designated/Approved on an active designation row, it is excluded from the definition of a covered outpatient drug for that hospital.

4. Differentiate Statutory Obligation from Voluntary Discounts: When an orphan product is excluded under § 256b(e), the manufacturer has no legal obligation under 42 U.S.C. § 256b(a)(1) to offer the 340B ceiling price. However, operations teams must confirm whether the manufacturer has voluntarily elected to offer a discounted price under 42 U.S.C. § 256b(a)(10).

flowchart TD
    A["Drug Purchase Transaction"] --> B["Step 1: Check OPAIS Entity Enrollment Type"]
    B --> C{"Is Entity Type Listed in 42 U.S.C. § 256b(e)?<br/>(CAH, RRC, SCH, or Free-Standing Cancer)"}
    C -- "No: DSH, Children's Hospital, FQHC, Ryan White" --> D["Exclusion Inapplicable<br/>340B(e) Does Not Remove COD Status"]
    C -- "Yes: CAH, RRC, SCH, Cancer Hospital" --> E["Step 2: Query FDA OOPD Database under 21 U.S.C. § 360bb"]
    E --> F{"Active OOPD Status?<br/>(Designated or Designated/Approved)"}
    F -- "No: Never Designated, Revoked, or Withdrawn" --> G["Not a 340B(e) Designated Product<br/>COD Analysis Continues Under SSA § 1927(k)"]
    F -- "Yes: Active Orphan Row in OOPD" --> H["Product Excluded from Covered Outpatient Drug Definition"]
    H --> I["Step 3: Statutory Duty Extinguished<br/>No 340B Ceiling-Price Mandate under § 256b(a)(1)"]
    I --> J{"Manufacturer Voluntary Offer<br/>under § 256b(a)(10)?"}
    J -- "Yes" --> K["Voluntary Discounted Price Available"]
    J -- "No" --> L["Not a 340B Ceiling-Price Purchase"]

The persistence of widespread confusion across healthcare systems stems directly from historical regulatory battles between HRSA and the pharmaceutical industry. For years, federal administrative guidance insisted that orphan drugs could be purchased at 340B prices if used for non-orphan clinical indications. That administrative stance was completely invalidated in federal court over a decade ago. Today, any compliance program that relies on clinical indication-tracking to justify 340B pricing on orphan drugs for excluded entity types operates in direct conflict with federal statute.

What 42 U.S.C. § 256b(e) actually excludes

The statutory exclusion of orphan drugs is codified at 42 U.S.C. § 256b(e), under the heading Exclusion of orphan drugs for certain covered entities. The statutory text is remarkably concise:

“For covered entities described in subparagraph (M) (other than a children’s hospital described in subparagraph (M)), (N), or (O) of subsection (a)(4), the term ‘covered outpatient drug’ shall not include a drug designated by the Secretary under section 360bb of title 21 for a rare disease or condition.”

To understand the mechanics of this exclusion, one must examine its legislative origin and statutory architecture. Section 256b(e) was added by Section 2302 of the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152, 124 Stat. 1082, March 30, 2010). Before that expansion, 340B hospital participation was concentrated in disproportionate-share hospitals, children's hospitals, and federal grantee clinics. When Congress added Critical Access Hospitals, rural referral centers, sole community hospitals, and free-standing cancer hospitals, the orphan-drug carve-out was the statutory offset for those newly eligible hospital types.

Congress responded by crafting a targeted statutory compromise. Newly eligible rural and cancer hospitals gained access to statutory 340B discounts on general outpatient pharmaceutical products. In exchange, Congress explicitly carved out orphan-designated drugs from the definition of a covered outpatient drug for those specific institutions. Months later, Congress recognized an unintentional drafting ambiguity in subparagraph (M) that threatened pediatric hospitals and enacted the Medicare and Medicaid Extenders Act of 2010 (Pub. L. 111-309, § 204(a)(1), 124 Stat. 3289), which explicitly inserted the parenthetical phrase: (other than a children’s hospital described in subparagraph (M)).

The central legal mechanism of § 256b(e) is its modification of the term covered outpatient drug (COD). Under 42 U.S.C. § 256b(b)(1), the 340B statute incorporates the definition of covered outpatient drug set forth in Section 1927(k) of the Social Security Act (42 U.S.C. § 1396r-8(k)). Section 1396r-8(k)(2) defines covered outpatient drugs as prescription drugs approved under Section 505 of the Federal Food, Drug, and Cosmetic Act (FFDCA), biological products licensed under Section 351 of the Public Health Service Act (PHSA) other than vaccines, and certified insulin. Section 1396r-8(k)(3) establishes general categorical limits, excluding drugs bundled into inpatient hospital stays where reimbursement is not direct and separate.

Section 256b(e) does not modify the general Medicaid definition in § 1396r-8(k). Instead, it establishes an entity-specific statutory carve-out. For the covered entities specified in subparagraphs (M) (excluding children's hospitals), (N), and (O), an orphan-designated drug ceases to be a covered outpatient drug under 340B. This distinction is critical because the mandatory ceiling-price requirement in 42 U.S.C. § 256b(a)(1) applies exclusively to covered outpatient drugs:

“Each such agreement shall require that the manufacturer offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price.”

By stripping an orphan-designated drug of its COD status when purchased by an excluded hospital category, Congress severed the statutory chain that compels the manufacturer to offer the 340B ceiling price. Crucially, the statutory text of § 256b(e) names only designation under 21 U.S.C. § 360bb. It contains no language regarding patient diagnosis, therapeutic indication, off-label prescribing, or market exclusivity. As a matter of basic statutory construction, the exclusion attaches to the product by virtue of its regulatory designation status, not the clinical circumstance of its administration.

Entity-type gate: four hospitals in, children’s hospitals and DSHs out

The primary sorting mechanism for 340B(e) is the statutory classification of the covered entity under 42 U.S.C. § 256b(a)(4). In the 2023 U.S. Code, that list runs through fifteen subparagraphs, (A) through (O). There is no subparagraph (P). Section 256b(e) does not apply to the 340B program as a whole; it applies exclusively to three of those subparagraphs:

• Subparagraph (M) — Free-Standing Cancer Hospitals: Hospitals excluded from the Medicare Inpatient Prospective Payment System (IPPS) under Section 1886(d)(1)(B)(v) of the Social Security Act that meet the requirements of subparagraph (L), including the disproportionate-share adjustment percentage threshold. Free-standing cancer hospitals are inside § 256b(e). Orphan drugs are excluded from 340B purchasing.

• Subparagraph (N) — Critical Access Hospitals (CAHs): Small rural facilities designated by states as critical access hospitals under Section 1820(c)(2) of the Social Security Act that meet the public ownership, governmental contract, or non-profit indigent care requirements of subparagraph (L)(i). CAHs are inside § 256b(e). Orphan drugs are excluded from 340B purchasing.

• Subparagraph (O) — Rural Referral Centers and Sole Community Hospitals: Rural Referral Centers (RRCs) classified under SSA § 1886(d)(5)(C)(i) and Sole Community Hospitals (SCHs) classified under SSA § 1886(d)(5)(C)(iii) that meet the indigent care requirements of (L)(i) and have a disproportionate share adjustment percentage of at least 8 percent. Both RRCs and SCHs are inside § 256b(e). Orphan drugs are excluded from 340B purchasing.

Conversely, every other covered entity category defined in 42 U.S.C. § 256b(a)(4) is entirely outside the scope of § 256b(e). Most notably, Disproportionate Share Hospitals (DSHs) enrolled under subparagraph (L) are not subject to the orphan-drug exclusion. When a DSH purchases an orphan-designated drug that is otherwise a covered outpatient drug, the manufacturer remains obligated under § 256b(a)(1) to offer the statutory 340B ceiling price.

Similarly, Children's Hospitals are fully exempt from the exclusion. Children's hospitals are legally defined in subparagraph (M) alongside cancer hospitals as facilities excluded from IPPS under SSA § 1886(d)(1)(B)(iii). However, because Congress explicitly enacted the statutory parenthetical (other than a children’s hospital described in subparagraph (M)), children's hospitals are completely carved out of § 256b(e). A compliance officer or purchaser who reviews subparagraph (M) without reading the parenthetical will reach a disastrously incorrect legal conclusion.

Product gate: designation is not approval and not exclusivity

Once an entity is identified as an excluded hospital type under § 256b(e), the analysis transitions to the product gate. The statute explicitly cross-references section 360bb of title 21—Section 526 of the Federal Food, Drug, and Cosmetic Act. Under 21 U.S.C. § 360bb, a pharmaceutical sponsor may request orphan designation for a drug intended to treat a rare disease or condition. The statute defines a rare disease or condition as one that affects fewer than 200,000 persons in the United States, or one that affects more than 200,000 persons but for which there is no reasonable expectation that development and marketing costs can be recovered from U.S. commercial sales.

Understanding the exact statutory mechanism requires distinguishing three regulatory concepts that are frequently conflated: orphan designation, marketing approval, and orphan exclusivity:

• Orphan Designation (21 U.S.C. § 360bb): Designation is an administrative status granted by FDA's Office of Orphan Products Development during clinical development. It confirms that the investigational agent meets statutory rare-disease prevalence criteria. Designation does not constitute marketing approval. A drug may be designated for a decade before receiving an approved New Drug Application (NDA) or Biologics License Application (BLA), or it may fail clinical trials and never be approved.

• Marketing Approval (21 U.S.C. § 355 / 42 U.S.C. § 262): Approval occurs when FDA determines that a drug or biologic is safe and effective for an indicated use. Only approved drugs can become covered outpatient drugs under SSA § 1927(k) and 42 U.S.C. § 256b(b)(1). An investigational compound that holds orphan designation but lacks FDA approval is not a COD to begin with; 340B pricing does not apply to unapproved investigational agents regardless of entity type.

• Orphan Exclusivity (21 U.S.C. § 360cc): Under Section 527 of the FFDCA (21 U.S.C. § 360cc), when an orphan-designated drug receives marketing approval for its designated rare disease, FDA grants seven years of market exclusivity. During this seven-year window, FDA may not approve another application for the same drug and the same rare disease. Orphan exclusivity is an intellectual property and commercial barrier. It is not the 340B(e) trigger.

The interaction between designation under § 360bb and exclusivity under § 360cc represents one of the most critical legal nuances in 340B compliance. When a drug's seven-year orphan exclusivity period expires, generic or biosimilar competitors may enter the market. However, exclusivity expiration does not revoke, cancel, or terminate the drug's orphan designation. Under 21 CFR 316.29, FDA revokes orphan designation only under very narrow circumstances: if the request contained untrue statements, omitted material facts, or if the drug was not eligible at the time of request. The regulation explicitly states that designation will not be revoked simply because disease prevalence subsequently exceeds 200,000.

Furthermore, under 21 CFR 316.23, a sponsor may obtain an orphan designation for an already-approved, blockbuster drug for an unapproved rare use, regardless of whether its original approval was for a common disease. Once FDA enters that designation into the public OOPD database, the product meets the statutory definition in 42 U.S.C. § 256b(e).

HRSA's June 2024 Orphan Drugs page instructs stakeholders to query FDA's searchable OOPD database. The page's steps are: search results “All designations,” output format “Download Excel File,” then filter the Orphan Designation Status field to two specific values: Designated and Designated/Approved. If a drug row displays either status, HRSA treats the drug as an excluded orphan product for the four hospital types.

Why SERPs still say “use”: the vacated 2013 rule and 2014 interpretive rule

A routine search-engine inquiry regarding 340B orphan-drug rules still returns vendor whitepapers, webinars, and pharmacy trade articles asserting that covered entities may purchase orphan drugs at 340B ceiling prices so long as the medication is prescribed for a non-orphan disease. Those materials often describe electronic health record split-billing algorithms designed to track patient diagnoses and route claims into separate 340B and commercial accounts based on the prescribed indication. That use-based construction is the vacated 2013/2014 HHS reading, not the statute now in force.

The origin of this persistent error lies in the regulatory response of the Department of Health and Human Services (HHS) following the enactment of the Affordable Care Act. Recognizing that many orphan-designated drugs (such as rituximab, bevacizumab, and fluoxetine) are widely prescribed for common non-orphan illnesses, rural hospitals and cancer advocates petitioned HHS to interpret § 256b(e) narrowly. On July 23, 2013, HHS published a final legislative rule titled Exclusion of Orphan Drugs for Certain Covered Entities Under 340B Program (78 FR 44016), codified at then-42 CFR § 10.21. Under that rule, HHS declared that the orphan-drug exclusion applied only when an orphan drug was “transferred, prescribed, sold, or otherwise used for the rare condition or disease for which the drug was designated.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) immediately filed a federal lawsuit challenging the regulation. In PhRMA v. HHS, 43 F. Supp. 3d 28 (D.D.C. May 23, 2014), U.S. District Judge Rudolph Contreras struck down the rule. The court held that the 340B statute does not grant HHS broad legislative rulemaking authority. Congress granted HHS explicit rulemaking power in only three highly specific areas: establishing an Administrative Dispute Resolution (ADR) process, issuing ceiling-price calculation methodologies, and imposing manufacturer civil monetary penalties. Because Congress did not authorize substantive rulemaking for the orphan-drug exclusion, the 2013 final rule was vacated for lack of statutory authority.

Refusing to concede the policy battle, HHS issued an interpretive rule on July 23, 2014 (79 FR 42801), asserting the exact same substantive position: that § 256b(e) excluded orphan drugs only when used for the designated rare disease. Because interpretive rules do not require statutory delegations of notice-and-comment rulemaking power, HHS believed it had successfully sidestepped the court's 2014 decision.

PhRMA filed a second lawsuit. In PhRMA v. HHS, 138 F. Supp. 3d 31 (D.D.C. Oct. 14, 2015), Judge Contreras dealt a definitive legal blow to the agency's interpretation. Reviewing the interpretive rule under the Administrative Procedure Act (5 U.S.C. § 706(2)(A)), the court held that HHS's use-based interpretation was flatly contrary to the unambiguous plain language of 42 U.S.C. § 256b(e):

“By its plain terms, the orphan drug exclusion applies to a drug that is ‘designated . . . for a rare disease or condition.’ The section refers only to the designation of that drug, and makes no mention of whether the so-designated drug is in fact used by the covered entity to treat the rare disease or condition for which it was designated.”

To show that Congress knew how to write a use limit when it wanted one, the court compared other provisions. In the Medicare OPPS pass-through statute (42 U.S.C. § 1395l(t)(6)(A)(i)), Congress limited the benefit to a designated orphan drug that is used for a rare disease or condition. In the Internal Revenue Code (26 U.S.C. § 45C), Congress restricted clinical testing credits to expenses for rare conditions. Quoting Hall v. United States, 566 U.S. 506, 132 S. Ct. 1882, 1893 (2012), the court stated: “But if Congress intended that result, it did not so provide in the statute.” The court vacated the 2014 interpretive rule under 5 U.S.C. § 706(2)(A).

Today, 42 CFR Part 10 contains no regulation governing orphan drugs. If an audit team or compliance officer opens the current Electronic Code of Federal Regulations (eCFR), 42 CFR § 10.21 is titled Claims and sits in Subpart C (Administrative Dispute Resolution). It defines claims by a covered entity that a manufacturer overcharged or limited ceiling-price access, and manufacturer claims after audit for duplicate-discount or diversion violations. The 2013 orphan-drug text is gone. Citing an old PDF of 42 CFR 10.21 or a 2013 law-firm advisory as current orphan-drug law is a documentation defect.

Worked record: one fictional 340B ID and one OOPD row

The worksheet below is a labeled hypothetical. The four entity IDs are fictional labels only; they are not OPAIS listings, do not determine any real hospital’s 340B enrollment, and are not legal, coverage, or reimbursement advice. No proprietary pricing, claims data, or current manufacturer offer is invented. The product row is the public FDA OOPD record for rituximab (cfgridkey 79793), accessed 19 September 2026.

The four fictional covered-entity archetypes represent the critical statutory dividing lines under 42 U.S.C. § 256b(a)(4):

• Entity A (CAH-EXAMPLE-00): A municipal Critical Access Hospital enrolled under § 256b(a)(4)(N).

• Entity B (DSH-EXAMPLE-00): An urban teaching Disproportionate Share Hospital enrolled under § 256b(a)(4)(L).

• Entity C (PED-EXAMPLE-00): A non-profit Children's Hospital enrolled under § 256b(a)(4)(M).

• Entity D (CAN-EXAMPLE-00): A specialized Free-Standing Cancer Hospital enrolled under § 256b(a)(4)(M).

All four entities seek to purchase rituximab (Rituxan, CF Grid Key 79793). Rituximab holds an active designation in FDA's OOPD database for the treatment of non-Hodgkin's B-cell lymphoma (NHL) with status Designated/Approved. In addition, rituximab possesses full FDA approval for rheumatoid arthritis (RA), a prevalent non-orphan autoimmune disorder.

The purchasing desk evaluates two clinical scenarios for each hospital: Clinical Scenario 1 involves an outpatient infusion for a patient diagnosed with non-Hodgkin's lymphoma. Clinical Scenario 2 involves an outpatient infusion for a patient diagnosed with severe rheumatoid arthritis. The matrix below records the objective determination across all five statutory criteria:

The audit matrix illustrates three vital operational conclusions:

• Diagnosis Irrelevance for Excluded Facilities: For CAH-EXAMPLE-00 and CAN-EXAMPLE-00, the statutory ceiling-price obligation under § 256b(a)(1) is absent under both scenarios. It is entirely irrelevant that the patient in Scenario 2 received rituximab for rheumatoid arthritis. Because rituximab holds an active designation in OOPD, § 256b(e) strips the drug of its covered outpatient drug status for those two facilities, extinguishing the statutory pricing mandate across all clinical uses.

• DSH and Children's Hospitals Stay Outside 340B(e): For DSH-EXAMPLE-00 and PED-EXAMPLE-00, § 256b(e) does not apply. If rituximab is otherwise a covered outpatient drug, the manufacturer must offer it at or below the statutory 340B ceiling price for both the lymphoma and rheumatoid-arthritis rows. Children's hospitals are outside the exclusion because of the express parenthetical in § 256b(e), not because of the later claim diagnosis.

• Biosimilar Verification Requirements: Hospital purchasers must not assume that biosimilars automatically inherit the orphan designation status of their reference product. Orphan designation is granted to a specific sponsor for a specific investigational application. When purchasing a biosimilar (such as rituximab-abbs or rituximab-pvvr), the purchasing desk must look up the biosimilar sponsor's specific regulatory record in OOPD. If a biosimilar sponsor never applied for or received orphan designation, the biosimilar is not an orphan-designated product under 21 U.S.C. § 360bb and is not excluded under § 256b(e).

Overlays that are not this decision

In daily pharmacy procurement and healthcare compliance, operators frequently conflate Section 340B(e) with adjacent statutory requirements, pricing rules, and billing policies. Maintaining audit-ready records requires isolating the orphan exclusion from six distinct legal frameworks:

The Group Purchasing Organization (GPO) Prohibition

Under 42 U.S.C. § 256b(a)(4)(L)(iii), Disproportionate Share Hospitals, Children's Hospitals, and Free-Standing Cancer Hospitals are strictly prohibited from purchasing covered outpatient drugs through a Group Purchasing Organization (GPO). In contrast, HRSA guidance explicitly confirms that the GPO prohibition does not apply to Critical Access Hospitals, Rural Referral Centers, or Sole Community Hospitals.

The intersection of the GPO prohibition and § 256b(e) creates an intriguing statutory paradox for Free-Standing Cancer Hospitals. Because § 256b(e) excludes orphan-designated drugs from the definition of a covered outpatient drug for cancer hospitals, an orphan-designated drug purchased by a cancer hospital is not a covered outpatient drug. Consequently, a free-standing cancer hospital that purchases an orphan drug through a GPO does not violate the statutory GPO prohibition. However, the cancer hospital remains strictly barred from using a GPO for any non-orphan covered outpatient drugs. Attempting to apply this logic to a DSH hospital is an immediate violation, because DSH hospitals remain subject to the GPO prohibition across all covered outpatient drugs, including orphan products.

Medicaid Duplicate Discounts and Diversion

Under 42 U.S.C. § 256b(a)(5)(A), covered entities must not cause a manufacturer to pay a duplicate Medicaid discount—specifically, obtaining a 340B ceiling price while simultaneously billing Medicaid fee-for-service where the state claims a statutory rebate under SSA § 1927. Under § 256b(a)(5)(B), entities are prohibited from reselling or transferring 340B drugs to individuals who are not eligible patients.

These core compliance rules apply to medications actually purchased under the 340B program. When a Critical Access Hospital buys a designated orphan product outside 340B because § 256b(e) removed it from the covered-outpatient-drug definition, that purchase is not a 340B claim. Duplicate-discount liability under Section 340B does not arise in the same way on a non-340B unit, and this article does not invent a Medicaid-rebate outcome for the fictional worksheet. For Medicaid best-price mechanics in a different setting, see Medicaid best-price risk in value-based drug contracts.

Voluntary Manufacturer Discounts under § 256b(a)(10)

A common misconception among hospital purchasers is that 42 U.S.C. § 256b(e) prohibits manufacturers from selling orphan drugs at discounted prices to rural hospitals. The statute does nothing of the sort. Section 256b(e) merely relieves the manufacturer of its mandatory obligation under § 256b(a)(1) to cap prices at the statutory 340B ceiling formula.

Under 42 U.S.C. § 256b(a)(10), nothing in subsection (a) prohibits a manufacturer from charging a price lower than the statutory maximum. A manufacturer may still choose to discount designated products to the excluded hospital types. HRSA's June 2024 orphan page restates that permission: “A manufacturer may choose to offer discounts on orphan drugs to these hospitals.” This article does not publish a current named-manufacturer offer list.

The Inflation Reduction Act (IRA) Orphan Drug Exclusion

Under the Medicare Drug Price Negotiation Program established by the Inflation Reduction Act of 2022 (42 U.S.C. § 1320f-1(e)(3)(A)), Congress created an orphan-drug exemption from Medicare price negotiation. That provision excludes qualifying single-source drugs that hold orphan designation under 21 U.S.C. § 360bb for only one rare disease or condition and whose only approved indications are for that specific rare disease (subsequently amended in 2025 reconciliation legislation to adjust multi-designation rules for Initial Price Applicability Year 2028 and beyond).

The IRA negotiation orphan exclusion is a federal Medicare price-setting rule administered by CMS. It is completely independent of 42 U.S.C. § 256b(e). A pharmaceutical product can be fully eligible for Medicare negotiation under the IRA while remaining excluded from 340B purchasing for Critical Access Hospitals under § 256b(e). Conversely, a drug with multiple approved orphan indications may lose its IRA negotiation exemption while remaining fully accessible under 340B to DSH hospitals. For an analysis of manufacturer non-duplication workflows under the IRA Maximum Fair Price (MFP), see 340B and IRA MFP non-duplication workflow for manufacturer teams, and our review of the IRA Medicare drug negotiation third cycle: 15 drugs selected for 2028.

CMS Discarded-Drug Waste Billing (Modifiers JW and JZ)

Under Medicare Part B billing rules, outpatient hospitals must append HCPCS modifier JW to report discarded drug units from single-dose vials or modifier JZ to attest that no drug units were discarded. While both Part B waste reporting and 340B procurement involve outpatient hospital billing, modifier JW/JZ reporting has no legal connection to 42 U.S.C. § 256b(e). A hospital must comply with Part B billing rules regardless of whether the administered drug was purchased at 340B ceiling prices, under a voluntary discount, or at commercial wholesale rates.

Manufacturer Rebate Models and Contract Pharmacies

Recent federal litigation and administrative updates have reshaped the broader 340B landscape, including the D.C. Circuit's July 2026 ruling regarding manufacturer 340B rebate models and contract pharmacy fulfillment networks. For detailed operational guidance on manufacturer rebate models and court precedents, consult our report on 340B Rebate-Model Ruling: D.C. Circuit Puts HHS in the Driver's Seat (2026), the regulatory updates in CMS's 340B OPPS Cut: ASP Minus 33.4%, the 2026 Survey, and August 31 Clock, and the upcoming CMS Part D 340B Repository: Voluntary Files Do Not Replace Prescriber Math.

Sources

Primary statutory authorities, federal court decisions, administrative regulations, and official federal databases governing 42 U.S.C. § 256b(e):

• 42 U.S.C. § 256b — Limitation on prices of drugs purchased by covered entities (2023 U.S. Code, GPO). Sections 256b(a)(1) (pricing obligation), 256b(a)(4) (covered entity definitions), 256b(a)(10) (voluntary discounts), and 256b(e) (orphan drug exclusion).

• 21 U.S.C. § 360bb — Designation of drugs for rare diseases or conditions (2023 U.S. Code, GPO). FFDCA Section 526 orphan drug designation criteria and public notice requirements.

• 21 U.S.C. § 360cc — Protection for drugs for rare diseases or conditions (2023 U.S. Code, GPO). FFDCA Section 527 seven-year orphan market exclusivity terms.

• 42 U.S.C. § 1396r-8 — Payment for covered outpatient drugs (Social Security Act § 1927(k) definitions of covered outpatient drugs incorporated into 340B).

• Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010, § 2302 (124 Stat. 1082, March 30, 2010). Legislative enactment adding 42 U.S.C. § 256b(e).

• Pub. L. 111-309, Medicare and Medicaid Extenders Act of 2010, § 204 (124 Stat. 3289, December 15, 2010). Technical amendment inserting the children's hospital parenthetical carve-out into § 256b(e).

• HRSA — Orphan Drugs (340B Program Requirements) (Content last reviewed June 2024; accessed September 19, 2026). Official HRSA guidance identifying excluded hospital types, voluntary discounts, and OOPD search filtering instructions.

• HRSA — 340B Eligibility and Registration (Guidance on OPAIS covered entity categories and annual recertification standards).

• FDA — Search Orphan Drug Designations and Approvals (OOPD) (Official FDA database for querying active, designated, approved, and revoked orphan drug records).

• FDA OOPD — Detailed Record for Rituximab (cfgridkey 79793) (Designated June 13, 1994, approved November 26, 1997, exclusivity expired November 26, 2004; status Designated/Approved).

• 21 CFR 316.23 — Timing of requests for orphan-drug designation (eCFR). Procedures for designating already-approved drugs for unapproved rare indications.

• 21 CFR 316.29 — Revocation of orphan-drug designation (eCFR). Grounds for designation revocation; confirmation that increased prevalence does not revoke status.

• 42 CFR Part 10 — 340B Drug Pricing Program (eCFR, accessed September 19, 2026). Part 10 regulations establishing ADR procedures under § 10.21.

• PhRMA v. HHS, 43 F. Supp. 3d 28 (D.D.C. 2014) (Civ. No. 13-1501 (RC)). Decision vacating 2013 legislative rule (78 FR 44016) for lack of statutory rulemaking authority.

• PhRMA v. HHS, 138 F. Supp. 3d 31 (D.D.C. 2015) (Civ. No. 14-1685 (RC)). Decision vacating 2014 interpretive rule (79 FR 42801) as contrary to the plain text of 42 U.S.C. § 256b(e).

• Astra USA, Inc. v. Santa Clara County, 563 U.S. 110 (2011) (Supreme Court ruling clarifying 340B statutory framework and Pharmaceutical Pricing Agreements).

• 42 U.S.C. § 1320f-1 — Selection of negotiation-eligible drugs (Medicare Drug Price Negotiation Program orphan exception provisions under the Inflation Reduction Act).